Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CovenD24 Dose Study in Moderate/Severe COVID-19
NCT04902183Phase 2Unknown
- Sponsor
- Athens Medical Society
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of exosomes overexpressing CD24 in coronavirus disease 2019 (COVID-19), sponsored by Athens Medical Society. Status: unknown.
02
Drugs
exosomes overexpressing CD24
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04902183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902183.